ABUS vs L · P/E 5.4, rev $6.2M vs P/E 14, rev $18.45B
Arbutus Biopharma Corp (ABUS) versus Loews Corp (L) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Loews Corp (L) is a insurance - property & casualty company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported L revenue for 2025-12-31 was $18.45B. Net income was $1.67B. Revenue was up 5.4% from 2024-12-31 to 2025-12-31. L currently screens at market cap $22.36B and trailing P/E 13.8.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. L currently screens at market cap $22.36B and trailing P/E 13.8.
Not investment advice. Open the ABUS and L stock pages for the full models.
Not investment advice.